Per‐Ola Andersson

2.8k total citations · 1 hit paper
72 papers, 2.1k citations indexed

About

Per‐Ola Andersson is a scholar working on Pathology and Forensic Medicine, Oncology and Hematology. According to data from OpenAlex, Per‐Ola Andersson has authored 72 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Pathology and Forensic Medicine, 22 papers in Oncology and 21 papers in Hematology. Recurrent topics in Per‐Ola Andersson's work include Lymphoma Diagnosis and Treatment (31 papers), Chronic Lymphocytic Leukemia Research (17 papers) and Viral-associated cancers and disorders (10 papers). Per‐Ola Andersson is often cited by papers focused on Lymphoma Diagnosis and Treatment (31 papers), Chronic Lymphocytic Leukemia Research (17 papers) and Viral-associated cancers and disorders (10 papers). Per‐Ola Andersson collaborates with scholars based in Sweden, United States and Germany. Per‐Ola Andersson's co-authors include Hans Wadenvik, Stefan Jacobsson, Lena Carlsson, Bob Olsson, Margareta Jernås, Björn Carlsson, Sverker Hasselblom, Herman Nilsson‐Ehle, Börje Ridell and Ulrika Hansson and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Per‐Ola Andersson

71 papers receiving 2.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura

2003 519 citations Bob Olsson, Per‐Ola Andersson et al. Nature Medicine profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Per‐Ola Andersson	876	671	524	511	425	72	2.1k
CH Pui	2.0k 2.2×	539 0.8×	613 1.2×	952 1.9×	515 1.2×	64	3.8k
S.A. Johnson	425 0.5×	587 0.9×	456 0.9×	411 0.8×	774 1.8×	35	2.0k
Virginie Penard‐Lacronique	977 1.1×	235 0.4×	829 1.6×	1.4k 2.8×	592 1.4×	44	2.8k
Juerg Schwaller	1.3k 1.5×	844 1.3×	1.2k 2.3×	2.1k 4.0×	569 1.3×	66	3.8k
Laurence Elias	761 0.9×	1.2k 1.9×	806 1.5×	914 1.8×	1.4k 3.4×	72	3.2k
RJ Jones	1.7k 1.9×	319 0.5×	941 1.8×	725 1.4×	688 1.6×	33	2.8k
Martín Pérez‐Andrés	657 0.8×	198 0.3×	401 0.8×	638 1.2×	281 0.7×	63	1.8k
Tibor Kovacsovics	2.3k 2.6×	261 0.4×	880 1.7×	1.4k 2.7×	639 1.5×	123	3.7k
Tobias Dechow	275 0.3×	358 0.5×	793 1.5×	692 1.4×	246 0.6×	73	2.0k
Nelly Robillard	1.7k 2.0×	488 0.7×	1.2k 2.3×	1.6k 3.1×	641 1.5×	94	3.8k

Countries citing papers authored by Per‐Ola Andersson

Since Specialization

Citations

This map shows the geographic impact of Per‐Ola Andersson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Per‐Ola Andersson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Per‐Ola Andersson more than expected).

Fields of papers citing papers by Per‐Ola Andersson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Per‐Ola Andersson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Per‐Ola Andersson. The network helps show where Per‐Ola Andersson may publish in the future.

Co-authorship network of co-authors of Per‐Ola Andersson

This figure shows the co-authorship network connecting the top 25 collaborators of Per‐Ola Andersson. A scholar is included among the top collaborators of Per‐Ola Andersson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Per‐Ola Andersson. Per‐Ola Andersson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Uggla, Bertil, Camilla Virta, Merit Melin, et al.. (2025). Revaccination with pneumococcal conjugate vaccine five years after primary immunization improves immunity in patients with chronic lymphocytic leukemia. Haematologica. 110(8). 1774–1785. 1 indexed citations

Einarsdottir, Sigrun, Krista Vaht, Tomas Bergström, et al.. (2023). Long-Term Immunity Against Tetanus and Diphtheria after Vaccination of Allogeneic Stem Cell Transplantation Recipients. Transplantation and Cellular Therapy. 29(4). 275.e1–275.e5. 2 indexed citations

Weibull, Caroline E., Tove Wästerlid, Björn E. Wahlin, et al.. (2023). Survival by First-line Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A National Population-based Study in Sweden. HemaSphere. 7(3). e838–e838. 5 indexed citations

Eloranta, Sandra, Sara Ekberg, Gunilla Enblad, et al.. (2022). Outcomes of relapsed/refractory diffuse large B‐cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line—A population‐based study of 736 patients. British Journal of Haematology. 198(2). 267–277. 20 indexed citations

Sadik, May, Johannes Ulén, Olof Enqvist, et al.. (2022). Artificial Intelligence Increases the Agreement among Physicians Classifying Focal Skeleton/Bone Marrow Uptake in Hodgkin’s Lymphoma Patients Staged with [18F]FDG PET/CT—a Retrospective Study. Nuclear Medicine and Molecular Imaging. 57(2). 110–116. 4 indexed citations

Ekberg, Sara, Tomas Jernberg, Karolina Szummer, et al.. (2021). Myocardial infarction in diffuse large B‐cell lymphoma patients – a population‐based matched cohort study. Journal of Internal Medicine. 290(5). 1048–1060. 10 indexed citations

Veskovski, Ljupco, Per‐Ola Andersson, Ingemar Turesson, et al.. (2021). Serum metabolomic profiling correlated with ISS and clinical outcome for multiple myeloma patients treated with high-dose melphalan and autologous stem cell transplantation. Experimental Hematology. 97. 79–88.e8. 7 indexed citations

Wästerlid, Tove, Therése Andersson, Sara Ekberg, et al.. (2020). Outcome and determinants of failure to complete primary R‐CHOP treatment for reasons other than non‐response among patients with diffuse large B‐cell lymphoma. American Journal of Hematology. 95(7). 740–748. 12 indexed citations

Ekberg, Sara, Mats Jerkeman, Per‐Ola Andersson, et al.. (2018). Long‐term survival and loss in expectancy of life in a population‐based cohort of 7114 patients with diffuse large B‐cell lymphoma. American Journal of Hematology. 93(8). 1020–1028. 19 indexed citations

10.

Johansson, Hemming, Jenny Klintman, Eva Kimby, et al.. (2018). First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013. Haematologica. 104(4). 797–804. 28 indexed citations

11.

Holzmann, Martin J., et al.. (2018). HIGH-SENSITIVITY TROPONINS AND OUTCOMES AFTER MYOCARDIAL INFARCTION. Journal of the American College of Cardiology. 71(11). A238–A238. 1 indexed citations

12.

Andersson, Per‐Ola, Karin Karlsson, Claes Karlsson, et al.. (2017). Real-World Results on Ibrutinib in Relapsed/Refractory CLL: A 21-Month Follow-up of 95 Swedish Patients Treated in a Compassionate Use Program. Blood. 130. 5353. 2 indexed citations

13.

Subhash, Santhilal, Per‐Ola Andersson, Subazini Thankaswamy Kosalai, Chandrasekhar Kanduri, & Meena Kanduri. (2016). Global DNA methylation profiling reveals new insights into epigenetically deregulated protein coding and long noncoding RNAs in CLL. Clinical Epigenetics. 8(1). 106–106. 41 indexed citations

14.

Norin, Stefan, et al.. (2014). Severe infusion-related reactions are uncommon in rituximab-treated CLL patients in clinical practice: Results from a Swedish national observational study. Leukemia Research. 39(1). 33–37. 4 indexed citations

15.

Grankvist, Anna, Per‐Ola Andersson, Mattias Mattsson, et al.. (2014). Infections With the Tick-Borne Bacterium "Candidatus Neoehrlichia mikurensis" Mimic Noninfectious Conditions in Patients With B Cell Malignancies or Autoimmune Diseases. Clinical Infectious Diseases. 58(12). 1716–1722. 79 indexed citations

16.

Kanduri, Meena, Millaray Marincevic, Anna Margrét Halldórsdóttir, et al.. (2012). Distinct transcriptional control in major immunogenetic subsets of chronic lymphocytic leukemia exhibiting subset-biased global DNA methylation profiles. Epigenetics. 7(12). 1435–1442. 29 indexed citations

17.

Hasselblom, Sverker, et al.. (2007). The number of tumour‐infiltrating TIA‐1+ cytotoxic T cells but not FOXP3+ regulatory T cells predicts outcome in diffuse large B‐cell lymphoma. British Journal of Haematology. 137(4). 364–373. 58 indexed citations

18.

Andersson, Per‐Ola, Stefan Jacobsson, Lena Carlsson, Hans Wadenvik, & Bob Olsson. (2004). Disturbed apoptosis of T-cells in patients with active idiopathic thrombocytopenic purpura. Thrombosis and Haemostasis. 93(1). 139–144. 57 indexed citations

19.

Olsson, Bob, Per‐Ola Andersson, Margareta Jernås, et al.. (2003). T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nature Medicine. 9(9). 1123–1124. 519 indexed citations breakdown →

20.

Andersson, Per‐Ola, Anna Olsson, & Hans Wadenvik. (2002). Reduced transforming growth factor‐β1 production by mononuclear cells from patients with active chronic idiopathic thrombocytopenic purpura. British Journal of Haematology. 116(4). 862–867. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact